Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy.

Karam JA, Fan J, Stanfield J, Richer E, Benaim EA, Frenkel E, Antich P, Sagalowsky AI, Mason RP, Hsieh JT.

Int J Cancer. 2007 Apr 15;120(8):1795-802.

2.

Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo.

Sasakawa Y, Naoe Y, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S.

Biochem Pharmacol. 2002 Oct 1;64(7):1079-90.

PMID:
12234611
3.

Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.

Li LH, Zhang PR, Cai PY, Li ZC.

Biomed Pharmacother. 2016 Aug;82:161-6. doi: 10.1016/j.biopha.2016.04.053. Epub 2016 May 9.

PMID:
27470351
4.

Histone deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family gene therapy in cancer models.

Sasaki Y, Negishi H, Idogawa M, Suzuki H, Mita H, Toyota M, Shinomura Y, Imai K, Tokino T.

Mol Cancer Ther. 2008 Apr;7(4):779-87. doi: 10.1158/1535-7163.MCT-07-0395.

5.
6.

Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression.

Nishida K, Komiyama T, Miyazawa S, Shen ZN, Furumatsu T, Doi H, Yoshida A, Yamana J, Yamamura M, Ninomiya Y, Inoue H, Asahara H.

Arthritis Rheum. 2004 Oct;50(10):3365-76.

7.

Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo.

Sasakawa Y, Naoe Y, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S.

Cancer Lett. 2003 Jun 10;195(2):161-8.

PMID:
12767524
8.

Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors.

Sasakawa Y, Naoe Y, Noto T, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S.

Biochem Pharmacol. 2003 Sep 15;66(6):897-906.

PMID:
12963476
9.

Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin.

Shang D, Liu Y, Matsui Y, Ito N, Nishiyama H, Kamoto T, Ogawa O.

Urology. 2008 Jun;71(6):1220-5. doi: 10.1016/j.urology.2007.11.029.

PMID:
18538698
10.

Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells.

Kanzaki M, Kakinuma H, Kumazawa T, Inoue T, Saito M, Narita S, Yuasa T, Tsuchiya N, Habuchi T.

Oncol Rep. 2007 Apr;17(4):761-7.

PMID:
17342312
11.

Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.

Ahrens TD, Timme S, Hoeppner J, Ostendorp J, Hembach S, Follo M, Hopt UT, Werner M, Busch H, Boerries M, Lassmann S.

Epigenetics. 2015;10(5):431-45. doi: 10.1080/15592294.2015.1039216.

12.

Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.

Hoshino I, Matsubara H, Hanari N, Mori M, Nishimori T, Yoneyama Y, Akutsu Y, Sakata H, Matsushita K, Seki N, Ochiai T.

Clin Cancer Res. 2005 Nov 1;11(21):7945-52.

13.

A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer.

Shieh JM, Tang YA, Hu FH, Huang WJ, Wang YJ, Jen J, Liao SY, Lu YH, Yeh YL, Wang TW, Lin P, Wang YC.

Int J Cancer. 2017 May 15;140(10):2375-2386. doi: 10.1002/ijc.30664. Epub 2017 Mar 14.

PMID:
28233309
14.

Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228.

Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA, Schrump DS.

J Natl Cancer Inst. 2002 Apr 3;94(7):504-13.

PMID:
11929951
15.

Lack of preventive efficacy of FK228, a histone deacetylase inhibitor, against N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder carcinogenesis in p53+/- and p53+/+ mice.

Wei M, Wanibuchi H, Morimura K, Salim EI, Moku M, Doi K, Mitsuhashi M, Masuda C, Shen J, Kinoshita A, Fukushima S.

Anticancer Res. 2004 Mar-Apr;24(2B):785-90.

16.

Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors.

Sakimura R, Tanaka K, Nakatani F, Matsunobu T, Li X, Hanada M, Okada T, Nakamura T, Matsumoto Y, Iwamoto Y.

Int J Cancer. 2005 Sep 20;116(5):784-92.

18.

5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.

Scott SA, Dong WF, Ichinohasama R, Hirsch C, Sheridan D, Sanche SE, Geyer CR, Decoteau JF.

Leuk Res. 2006 Jan;30(1):69-76. Epub 2005 Jul 25.

PMID:
16043219
19.

Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo.

Sawa H, Murakami H, Kumagai M, Nakasato M, Yamauchi S, Matsuyama N, Tamura Y, Satone A, Ide W, Hashimoto I, Kamada H.

Acta Neuropathol. 2004 Jun;107(6):523-31. Epub 2004 Mar 16.

PMID:
15024582
20.

Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line.

Duo J, Ma Y, Wang G, Han X, Zhang C.

DNA Cell Biol. 2013 Apr;32(4):156-64. doi: 10.1089/dna.2012.1926. Epub 2013 Mar 1.

PMID:
23451817

Supplemental Content

Support Center